NCT06541847 - A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 7, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

January 31, 2028

Conditions

Neurofibromatosis Type 1

Interventions

DRUG

HLX-1502

Participants will take an oral dose three times a day (with or without food) for up to 24 cycles (A cycle is defined as 28 days)

Trial Locations (10)

19104

RECRUITING

Children's Hospital of Philadelphia, Philadelphia

20010

RECRUITING

Children's National Hospital, Washington D.C.

21287

RECRUITING

Johns Hopkins Hospital, Baltimore

35294

RECRUITING

University of Alabama at Birmingham, Birmingham

45229

RECRUITING

Cincinnati Children's Hospital Medical Center, Cincinnati

46202

RECRUITING

Indiana University, Indianapolis

60611

RECRUITING

Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago

60637

RECRUITING

University of Chicago, Chicago

63110

RECRUITING

Washington University School of Medicine, St Louis

90027

RECRUITING

Children's Hospital Los Angeles, Los Angeles

All Listed Sponsors

lead

Healx Limited

INDUSTRY